JP2024540062A - 抗ｃｌｄｎ１８．２抗体及びその用途 - Google Patents
抗ｃｌｄｎ１８．２抗体及びその用途 Download PDFInfo
- Publication number
- JP2024540062A JP2024540062A JP2024525253A JP2024525253A JP2024540062A JP 2024540062 A JP2024540062 A JP 2024540062A JP 2024525253 A JP2024525253 A JP 2024525253A JP 2024525253 A JP2024525253 A JP 2024525253A JP 2024540062 A JP2024540062 A JP 2024540062A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111307619.3 | 2021-11-05 | ||
| CN202111307619 | 2021-11-05 | ||
| PCT/CN2022/129834 WO2023078386A1 (zh) | 2021-11-05 | 2022-11-04 | 抗cldn18.2抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540062A true JP2024540062A (ja) | 2024-10-31 |
| JP2024540062A5 JP2024540062A5 (https=) | 2026-01-28 |
Family
ID=86240666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525253A Pending JP2024540062A (ja) | 2021-11-05 | 2022-11-04 | 抗ｃｌｄｎ１８．２抗体及びその用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240409629A1 (https=) |
| EP (1) | EP4428154A4 (https=) |
| JP (1) | JP2024540062A (https=) |
| KR (1) | KR20240099289A (https=) |
| CN (1) | CN118139888A (https=) |
| TW (1) | TW202323285A (https=) |
| WO (1) | WO2023078386A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024114667A1 (zh) * | 2022-11-30 | 2024-06-06 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体药物偶联物及其药物组合物和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD120303A1 (https=) | 1975-05-15 | 1976-06-05 | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| ES2979068T3 (es) * | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
| JP2021523090A (ja) * | 2018-03-09 | 2021-09-02 | 科済生物医薬（上海）有限公司Ｃａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． | 腫瘍を治療するための方法および組成物 |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| KR20210050547A (ko) * | 2018-08-27 | 2021-05-07 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 항-클라우딘18.2 항체 및 이의 용도 |
| JP2022511394A (ja) * | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法 |
| EP3872093A4 (en) * | 2018-10-22 | 2022-10-19 | Shanghai Genbase Biotechnology Co., Ltd. | ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF |
| BR112021011014A2 (pt) * | 2018-12-07 | 2021-08-31 | Zlip Holding Limited | Anticorpos anti-claudina e usos destes |
| EP3902824A4 (en) * | 2018-12-28 | 2023-01-04 | Sparx Therapeutics Inc. | FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| EP3960766A4 (en) | 2019-04-19 | 2022-12-07 | Keymed Biosciences Co.,Ltd. | ANTI-TUMOR THERAPEUTIC AGENT AND USE THEREOF |
| CN114206935B (zh) * | 2019-05-24 | 2024-01-12 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| KR102777693B1 (ko) * | 2019-07-17 | 2025-03-07 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Claudin18 항체 및 암 치료 방법 |
| JP7767270B2 (ja) * | 2019-08-20 | 2025-11-11 | スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド | 新規抗ｃｌｄｎ１８．２抗体 |
| CN112480248B (zh) * | 2020-11-24 | 2023-05-05 | 三优生物医药(上海)有限公司 | 与cld18a2特异性结合的分子 |
| CN113416260B (zh) * | 2021-04-14 | 2022-02-01 | 南京凯地医疗技术有限公司 | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 |
-
2022
- 2022-11-04 JP JP2024525253A patent/JP2024540062A/ja active Pending
- 2022-11-04 EP EP22889407.7A patent/EP4428154A4/en active Pending
- 2022-11-04 US US18/704,659 patent/US20240409629A1/en active Pending
- 2022-11-04 KR KR1020247016174A patent/KR20240099289A/ko active Pending
- 2022-11-04 WO PCT/CN2022/129834 patent/WO2023078386A1/zh not_active Ceased
- 2022-11-04 TW TW111142259A patent/TW202323285A/zh unknown
- 2022-11-04 CN CN202280072576.1A patent/CN118139888A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240099289A (ko) | 2024-06-28 |
| TW202323285A (zh) | 2023-06-16 |
| EP4428154A1 (en) | 2024-09-11 |
| WO2023078386A8 (zh) | 2024-02-01 |
| WO2023078386A1 (zh) | 2023-05-11 |
| EP4428154A4 (en) | 2026-04-08 |
| CN118139888A (zh) | 2024-06-04 |
| US20240409629A1 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11136413B2 (en) | PDL-1 antibody, pharmaceutical composition thereof, and uses thereof | |
| TWI854047B (zh) | 抗人Trop-2抗體及其應用 | |
| TWI859319B (zh) | 抗ｃｄ７３抗體及組合物 | |
| CN114181310B (zh) | 抗tigit抗体、其药物组合物及用途 | |
| WO2022100613A1 (zh) | 针对密蛋白18a2和cd3的双特异性抗体及其应用 | |
| JP2020504627A (ja) | 抗ｐｄ−１抗体及びその使用 | |
| CN116261590B (zh) | 抗cd3抗体以及其用途 | |
| US20240352153A1 (en) | Pharmaceutical composition and use | |
| JP7780521B2 (ja) | 抗ｔｉｇｉｔ抗体、その医薬組成物及び用途 | |
| US20250223353A1 (en) | Anti-pvrig antibody, pharmaceutical composition thereof and use thereof | |
| US20250368735A1 (en) | Bispecific antibody containing anti-cldn18.2 antibody, and pharmaceutical composition and use thereof | |
| KR20220167331A (ko) | 항-flt3 항체 및 조성물 | |
| CA3255478A1 (en) | Anti-tigit-anti-pvrig bispecific antibody, pharmaceutical composition thereof and use thereof | |
| JP2024540062A (ja) | 抗ｃｌｄｎ１８．２抗体及びその用途 | |
| KR20250130296A (ko) | 항-ccr8 항체 및 이의 용도 | |
| RU2844869C1 (ru) | Антитела против ror1 и родственные биспецифичные связывающие белки | |
| HK40096798A (zh) | 抗cldn18.2抗体、其药物组合物及用途 | |
| HK40089230A (zh) | 药物组合物及用途 | |
| WO2025228351A1 (zh) | 抗体，抗体药物偶联物及其用途 | |
| WO2025241702A1 (zh) | 靶向hla-g的抗体或其抗原结合片段及其应用 | |
| WO2025044937A1 (zh) | 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20251031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251104 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20251031 |